1 / 9

OpportunityAnalyzer: Non-Hodgkins B-Cell Lymphoma

The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL), currently revolves around multiple rounds of Rituxan-based chemotherapy. See full Report : http://bit.ly/1vMz8VJ

richa21
Télécharger la présentation

OpportunityAnalyzer: Non-Hodgkins B-Cell Lymphoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OpportunityAnalyzer: Non-Hodgkins B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 p To buy this Report Visit http://www.jsbmarketresearch.com

  2. Summary The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL), currently revolves around multiple rounds of Rituxan-based chemotherapy. • p

  3. Key Findings Imbruvica will gain significant patient share in the relapsed/refractory MCL market before expanding into the r/r FL setting. However, Zydelig’s time-to market advantage as well as potentially superior clinical profile in FL patients will result in Zydelig maintaining the market lead in these patients. There is significant opportunity for the new agents Imbruvica and Zydelig, which are delivered orally and would greatly increase patient convenience in addition to providing superior clinical benefit over chemoimmunotherapy regimens. • p

  4. Scope Overview of B-cell NHL, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines for DLBCL, FL, MZL and MCL. Annualized B-cell NHL (including DLBCL. FL. MZL and MCL) therapeutics market revenue, annual cost of therapy and patient share in the first-line and relapsed/refractory setting (as well as consolidation/maintenance for FL patients) forecast from 2013 to 2018. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market • p

  5. Reasons to buy Develop business strategies by understanding the trends shaping and driving the B-cell NHL therapeutics markets in the US and 5EU. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NHL therapeutics market in future. To know more about this report click here – http://www.jsbmarketresearch.com/healthcare-medical/r OpportunityAnalyzer-Non-Hodgkins-B-Cell-Lymphoma-Opportunity Analysis-and-Forecast-to-2018-123266 • p

  6. OpportunityAnalyzer: Non-Hodgkins B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 Disease Overview Disease Management Current Treatment Options Unmet Needs Assessment and Opportunity Analysis  • p

  7. Related Reports • CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Australia • EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 • Sickle Cell Disease Global Clinical Trials Review, H2, 2014 • Healthcare and Medical Market Research • p

  8. About JSB Market Research • JSB MARKET RESEARCH is an online repository of an extensive collection of market research reports available online. This online portal contains high-quality reports with well-researched and high-quality content on a wide range of industries. These market research reportshelp us give a detailed insight into new opportunities in the industry, prevailing market trends, competitor analysis and future prospects. • JSB’s reports are developed by the domain experts and publishers under a closely observed surveillance of industry specialists. Therefore, the researched data is well researched, well- organized and matching up to the best standards in the industry. Also JSB’s database consists of detailed insights of the leading players in the global market, products and trends • p

  9. Contact Us Support & General Inquiries Mail : support@jsbmarketresearch.com +91 - 998 729 5242 Billing Support Mail : billing@jsbmarketresearch.com +91 22 412 366 50 Website http://www.jsbmarketresearch.com • p

More Related